Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,414

The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.

Amyotrophic lateral sclerosis

Open access
Hardiman, Orla, Al-Chalabi, Ammar, Chio, Adriano, Corr, Emma M., Logroscino, Giancarlo, Robberecht, Wim, Shaw, Pamela J., Simmons, Zachary, van den Berg, Leonard H. · 2017 · Nature Reviews Disease Primers

Abstract

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood, although a subset of patients have familial disease and harbour mutations in genes that have various roles in neuronal function. Two possible disease-modifying therapies that can slow disease progression are available for ALS, but patient management is largely mediated by symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for dysarthria. Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which leads to progressive muscle weakness and paralysis. This Primer by Hardiman and colleagues provides a detailed overview of the epidemiology, pathophysiology and diagnosis of ALS, and discusses the management of both the motor and non-motor symptoms of this condition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrdp.2017.71

Cites

248 of 248 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. Wong, Y. C. & Holzbaur, E. L. Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc. Natl Acad. Sci. USA 111, E4439–E4448 (2014).
  2. Pizzo, E. et al. Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular localization of angiogenin to control growth and survival. J. Cell Sci. 126, 4308–4319 (2013).
  3. Garcia, M. L. et al. Mutations in neurofilament genes are not a significant primary cause of non-SOD1-mediated amyotrophic lateral sclerosis. Neurobiol. Dis. 21, 102–109 (2006). · doi:10.1016/j.nbd.2005.06.016
  4. Mastaglia, F. L. & Needham, M. Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J. Clin. Neurosci. 22, 6–13 (2015). · doi:10.1016/j.jocn.2014.09.012
  5. Juntas-Morales, R., Pageot, N., Alphandery, S. & Camu, W. The use of peripherally inserted central catheter in amyotrophic lateral sclerosis patients at a later stage. Eur. Neurol. 77, 87–90 (2017). · doi:10.1159/000454858
  6. Gladman, M., Dehaan, M., Pinto, H., Geerts, W. & Zinman, L. Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study. Neurology 82, 1674–1677 (2014). · doi:10.1212/wnl.0000000000000405

Cited by

See all 1,414

Metadata

Authors
Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H.
Venue
Nature Reviews Disease Primers
Published
2017-10-05
Volume
3
Issue
1
Pages
17071-17071
ISSN
2056-676X (ISSN-L)
OpenAlex
W4211041983
Cited by
1,414
References
248
FWCI
8.92
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.